Newcom S R, Tagra K K, Kadin M E
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Am J Pathol. 1992 Mar;140(3):709-18.
Activated lymphocytes and malignant lymphoma cells derived from them (Ki-1 positive lymphoma cells) share similar mechanisms of proliferation. To further examine the inhibitory role of endogenous transforming growth factor beta (TGF beta) in Ki-1 positive lymphoma cells, the authors studied anti-TGF beta antibodies and measured their effect on proliferation. A monoclonal antibody (T1A5) prepared against a unique antigenic epitope of high molecular weight Hodgkin's TGF beta and a polyclonal rabbit antibody prepared against highly purified 25,000 D porcine platelet TGF beta 1 were used. Both antibodies are shown here to inhibit the biological activity of Hodgkin's TGF beta and to crossreact with their respective antigens in immunoblotting. DNA synthesis by Ki-1 lymphoma cells was increased 138-fold by anti-TGF beta 1 antibody and 262-fold by anti-Hodgkin's TGF beta. Exogenous TGF beta 1 suppression was completely reversed by anti-TGF beta 1 antibody and IL-2-induced proliferation was markedly potentiated (41 fold). L-428 Reed-Sternberg cells secrete physiologically active TGF beta but have fewer than 500 TGF beta receptor sites per cell; no significant proliferative response was measured for either anti-TGF beta 1 or anti-Hodgkin's TGF beta. These results show the suppressive effect of exogenous TGF beta 1 on indolent Ki-1 lymphoma cells and suggest that the endogenous secretion of high molecular weight physiologically active TGF beta is important in maintaining the indolent nature of this low-grade Ki-1 positive lymphoma.
活化淋巴细胞及其衍生的恶性淋巴瘤细胞(Ki-1阳性淋巴瘤细胞)具有相似的增殖机制。为了进一步研究内源性转化生长因子β(TGF-β)对Ki-1阳性淋巴瘤细胞的抑制作用,作者研究了抗TGF-β抗体并测量了它们对增殖的影响。使用了针对高分子量霍奇金TGF-β独特抗原表位制备的单克隆抗体(T1A5)和针对高度纯化的25,000D猪血小板TGF-β1制备的兔多克隆抗体。本文显示这两种抗体均能抑制霍奇金TGF-β的生物活性,并在免疫印迹中与各自的抗原发生交叉反应。抗TGF-β1抗体使Ki-1淋巴瘤细胞的DNA合成增加了138倍,抗霍奇金TGF-β使其增加了262倍。抗TGF-β1抗体完全逆转了外源性TGF-β1的抑制作用,并且显著增强了IL-2诱导的增殖(41倍)。L-428里德-斯特恩伯格细胞分泌具有生理活性的TGF-β,但每个细胞的TGF-β受体位点少于500个;抗TGF-β1抗体或抗霍奇金TGF-β均未检测到明显的增殖反应。这些结果显示了外源性TGF-β1对惰性Ki-1淋巴瘤细胞的抑制作用,并表明高分子量具有生理活性的TGF-β的内源性分泌对于维持这种低级别Ki-1阳性淋巴瘤的惰性特性很重要。